“Groundbreaking Medicine for Alzheimer’s: Antisense Oligonucleotide Safely Reduces Tau Protein, Results Published in Nature Medicine and Phase 2 Study To Follow”

2023-04-26 18:42:43

medicine

Wednesday April 26, 2023

London – An antisense oligonucleotide that stops the production of tau proteins in nerve cells has been shown to be safe in a phase 1 study in patients with mild Alzheimer’s disease and significantly reduced the concentration of tau proteins in the cerebrospinal fluid. The results recently presented at a conference and now published in Nature Medicine (2023; DOI: 10.1038/s41591-023-02326-3) prompted the manufacturer to start a phase 2 study…